Sagility stake sale triggers share decline amid strong Q2 results
Sagility BV will sell a 12% stake via a block deal worth ₹2,377 crore at a discount, as the company reports a 22.5% revenue rise to Rs 2,032.1 crore for Q2 FY27. Shares fell following the announcement.

Sagility BV will sell a 12% stake in Sagility for approximately ₹2,377 crore through a block deal. The floor price is set at ₹42.45 per share, a discount of up to 4.9% to its closing price of ₹44.66 on the NSE on October 28, 2026. The transaction is scheduled for October 29, 2026.
Sagility reported a 22.5% year-on-year revenue increase to Rs 2,032.1 crore and an adjusted PAT of Rs 325.4 crore for Q2 FY27. The stock settled 1.4% lower on October 29.
Recent performance
Adjusted EBITDA increased 23% year-on-year to Rs 535.3 crore, with a margin of 26.3%. Basic EPS rose 13.3% to Rs 0.61, while adjusted basic EPS grew 8.1% to Rs 0.70. The company secured $40.2 million in annual contract value from 31 existing clients and one new client. It added 28 client groups in the first half of the fiscal year, bringing total active client groups to 105.
Srinivas Mattapalli said "the second quarter was marked by healthy growth, robust cash generation, and the company's highest adjusted EBITDA margin in six quarters." The board declared an interim dividend of Rs 0.15 per share. The company had 51,486 employees as of Q2 FY27 and a presence in five countries with 28 delivery centres.
Ownership changes
This proposed transaction marks another significant stake sale by the promoter. Following the deal, Sagility BV will be subject to a 365-day lock-up on its residual stake. Its holding will drop to 50.95%, down from 67.38% in the same period last year.
Recent shareholding activity includes BNP Paribas Financial Markets purchasing 35 lakh shares at an average price of ₹48.23 apiece on November 21, 2025. In a previous transaction on November 14, 2025, Sagility BV sold 76.9 crore shares at ₹47.60 apiece to institutional investors including Unifi Capital, Societe Generale, Norges Bank, Morgan Stanley Asia Singapore, and ICICI Prudential Mutual Fund.
Current non-promoter holdings include mutual funds with a 15.13% stake and general retail shareholders owning 16.1%.
Strategic expansion
The company's growth is being driven by strategic acquisitions and AI integration. It acquired Chirok Health LLC to strengthen its provider segment and revenue cycle management capabilities. This acquisition is expected to accelerate provider segment growth and strengthen end-to-end RCM.
AI solutions are gaining traction with new statement of work wins and production deployments. The CareSeed platform was integrated into Clinical Practice to enhance healthcare quality capabilities. Ramesh Gopalan said "the company's performance in the first half of FY27 reflected broad-based momentum across the business." The deal pipeline remained healthy with larger opportunities among Blues and mid-market health plans.
Market reaction
Shares declined 14% in 2026. On October 29, 2026, the stock settled 1.4% lower in the session. This follows a 1.17% drop to Rs 44.69 on the BSE from a previous close of Rs 45.22. The stock had recovered 24% from its yearly low of ₹35.83.
The company's price-to-earnings ratio stands at 20.33. For the quarter ended June 30, 2026, Sagility reported a 46% year-on-year rise in net profit to ₹217 crore. Revenue from operations increased 27.6% to ₹1,963 crore, while EBITDA rose 26.6% to ₹438 crore, though the EBITDA margin narrowed slightly to 22.3%. The company added 27 new clients in that quarter, bringing its total client base to 109.
The seller agreed to a 365-day lock-up on its remaining holding after the transaction.





